- Home
- KXIN vs LPCN Comparison
KXIN vs LPCN Comparison
Compare KXIN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- LPCN
- Stock Information
- Founded
- KXIN 2015
- LPCN 1997
- Country
- KXIN China
- LPCN United States
- Employees
- KXIN N/A
- LPCN N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- KXIN Consumer Discretionary
- LPCN Health Care
- Exchange
- KXIN Nasdaq
- LPCN Nasdaq
- Market Cap
- KXIN 16.9M
- LPCN 18.2M
- IPO Year
- KXIN N/A
- LPCN N/A
- Fundamental
- Price
- KXIN $0.67
- LPCN $3.11
- Analyst Decision
- KXIN
- LPCN Strong Buy
- Analyst Count
- KXIN 0
- LPCN 1
- Target Price
- KXIN N/A
- LPCN $8.00
- AVG Volume (30 Days)
- KXIN 265.7K
- LPCN 47.7K
- Earning Date
- KXIN 01-01-0001
- LPCN 11-06-2025
- Dividend Yield
- KXIN N/A
- LPCN N/A
- EPS Growth
- KXIN N/A
- LPCN N/A
- EPS
- KXIN N/A
- LPCN N/A
- Revenue
- KXIN $95,000.00
- LPCN $4,208,119.00
- Revenue This Year
- KXIN N/A
- LPCN N/A
- Revenue Next Year
- KXIN N/A
- LPCN N/A
- P/E Ratio
- KXIN N/A
- LPCN N/A
- Revenue Growth
- KXIN N/A
- LPCN N/A
- 52 Week Low
- KXIN $0.57
- LPCN $2.65
- 52 Week High
- KXIN $11.60
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- KXIN 48.97
- LPCN 54.39
- Support Level
- KXIN $0.59
- LPCN $3.03
- Resistance Level
- KXIN $0.69
- LPCN $3.21
- Average True Range (ATR)
- KXIN 0.05
- LPCN 0.18
- MACD
- KXIN -0.00
- LPCN 0.01
- Stochastic Oscillator
- KXIN 49.62
- LPCN 48.10
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.